Nebenwirkungen · Orgalutran
Orgalutran 0.25 mg/0.5 mL solution for injection · Abschnitt 4.8 · PDF-Seite 5
HOS-090737 · Präparat HOS-084109
Uncommon Malaise 1 Cases have been reported, as early as with the first dose, among patients administered Orgalutran. 2 Reported in one subject after the first Orgalutran dose. 3 In clinical studies, one hour after injection, the incidence of at least once a moderate or severe local skin reaction per treatment cycle, as reported by patients, was 12 % in Orgalutran treated patients and 25 % in patients treated subcutaneously with a GnRH agonist. The local reactions generally disappear within 4 hours after administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-18T17:19:00Z · SHA-256 d5745bf24c331ab2d63c32008ec32335d8d0ffea98e72a3c6106884d6c591d47 · Passage 0c76ff4c4a78765a5929ab8ad46e1919ebce9a5c4326fd3656a0c8863d040b38 · Zeichen 1518–2063 im Abschnitt